U.S. Markets close in 3 hrs 6 mins

Orexigen Therapeutics, Inc. (OREX)


NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
2.94-0.09 (-2.97%)
As of 12:45PM EDT. Market open.
People also watch
VVUSARNAKERXMNKDACHN
Interactive chart
Previous Close3.03
Open3.10
Bid2.96 x 100
Ask2.99 x 500
Day's Range2.93 - 3.10
52 Week Range1.65 - 6.50
Volume83,772
Avg. Volume242,145
Market Cap44.77M
Beta2.90
PE Ratio (TTM)-0.60
EPS (TTM)-4.87
Earnings DateAug 2, 2017 - Aug 7, 2017
Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est4.00
Trade prices are not sourced from all markets
  • The 3 Best Obesity-Drug Stocks to Buy in 2017
    Motley Fool4 days ago

    The 3 Best Obesity-Drug Stocks to Buy in 2017

    Looking for obesity-drug stocks to buy? Check out the biggest and best: Eisai, Novo Nordisk, and Roche.

  • Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth
    Zacks6 days ago

    Orexigen (OREX) Obesity Drug Contrave Registers Slow Growth

    On May 16, we issued an updated research report on La Jolla, CA based Orexigen Therapeutics, Inc. (OREX). Orexigen is a biopharmaceutical company focused on the development of obesity treatments.

  • PR Newswire7 days ago

    Orexigen Announces Activities at European Congress on Obesity 2017

    SAN DIEGO, May 16, 2017 /PRNewswire/ -- Orexigen Therapeutics, Inc. (OREX) announced today that the company will present two oral presentations on naltrexone HCl / bupropion HCl, marketed as Contrave® in the United States and Mysimba® in the European Union, at the 24th European Congress on Obesity (ECO) in Porto, Portugal on May 17 – 20, 2017. Orexigen is committed to leveraging its extensive alliance management capabilities to make Contrave/Mysimba available to patients who struggle to lose weight around the world.  The company has entered into strategic partnerships covering 44 countries outside the U.S.